Evolva reports additional Phase IIa data on EV-077

30-Aug-2012 - Switzerland

Evolva Holding SA announced further data for the first 32 patients enrolled in the Phase IIa study of its investigational drug, EV-077, a novel, reversible antagonist of isoprostanes and prostanoids. 16 patients received EV-077 and 16 patients received placebo.

The data indicate that 300mg EV-077 given orally twice daily to patients with type 2 diabetes provided anti-platelet activity, reduced exercise-induced proteinuria and increased forearm blood flow. This was achieved with only a slight increase in bleeding time. The analysis also indicates that EV-077 was generally well tolerated, with adverse events mostly limited to increases in liver enzymes, which were transient or resolved after discontinuation.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance